98 related articles for article (PubMed ID: 35738828)
21. Blocking the 5' splice site of exon 4 by a morpholino oligomer triggers APOL1 protein isoform switch.
Cheatham AM; Davis SE; Khatua AK; Popik W
Sci Rep; 2018 Jun; 8(1):8739. PubMed ID: 29880816
[TBL] [Abstract][Full Text] [Related]
22. Effect of
Haque S; Patil G; Mishra A; Lan X; Popik W; Malhotra A; Skorecki K; Singhal PC
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28385815
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of endoplasmic reticulum stress signaling rescues cytotoxicity of human apolipoprotein-L1 risk variants in Drosophila.
Gerstner L; Chen M; Kampf LL; Milosavljevic J; Lang K; Schneider R; Hildebrandt F; Helmstädter M; Walz G; Hermle T
Kidney Int; 2022 Jun; 101(6):1216-1231. PubMed ID: 35120995
[TBL] [Abstract][Full Text] [Related]
24. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
Sharma AK; Friedman DJ; Pollak MR; Alper SL
FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
[TBL] [Abstract][Full Text] [Related]
25. APOL1 localization in normal kidney and nondiabetic kidney disease.
Madhavan SM; O'Toole JF; Konieczkowski M; Ganesan S; Bruggeman LA; Sedor JR
J Am Soc Nephrol; 2011 Nov; 22(11):2119-28. PubMed ID: 21997392
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein L1 and kidney transplantation.
Tedla FM; Yap E
Curr Opin Organ Transplant; 2019 Feb; 24(1):97-102. PubMed ID: 30507707
[TBL] [Abstract][Full Text] [Related]
27. Genetics: APOL1 risk variants drive kidney disease in mice.
Allison SJ
Nat Rev Nephrol; 2017 May; 13(5):259. PubMed ID: 28262774
[No Abstract] [Full Text] [Related]
28. Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy.
Saraf SL; Zhang X; Shah B; Kanias T; Gudehithlu KP; Kittles R; Machado RF; Arruda JA; Gladwin MT; Singh AK; Gordeuk VR
Haematologica; 2015 Oct; 100(10):1275-84. PubMed ID: 26206798
[TBL] [Abstract][Full Text] [Related]
29. Genetic Testing for
Kopp JB; Winkler CA
Clin J Am Soc Nephrol; 2020 Jan; 15(1):126-128. PubMed ID: 31740572
[No Abstract] [Full Text] [Related]
30. Rapid detection and quantification of apolipoprotein L1 genetic variants and total levels in plasma by ultra-performance liquid chromatography/tandem mass spectrometry.
Zhou H; Hoek M; Yi P; Rohm RJ; Mahsut A; Brown P; Saunders J; Chmielowski RA; Ren N; Shuster D; Southwick K; Ayanoglu G; Gorman D; Laface D; Santino S; Conway J; Liu Z; Cully D; Cleary M; Roddy TP; Blom D
Rapid Commun Mass Spectrom; 2013 Dec; 27(23):2639-47. PubMed ID: 24591025
[TBL] [Abstract][Full Text] [Related]
31. [Novel insights into the role of APOL1 in the kidney].
Mohamadou I; Hertig A
Nephrol Ther; 2017 Dec; 13(7):569-571. PubMed ID: 29162341
[No Abstract] [Full Text] [Related]
32. APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?
Olabisi OA; Heneghan JF
Semin Nephrol; 2017 Nov; 37(6):546-551. PubMed ID: 29110762
[TBL] [Abstract][Full Text] [Related]
33. In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress.
Anderson BR; Howell DN; Soldano K; Garrett ME; Katsanis N; Telen MJ; Davis EE; Ashley-Koch AE
PLoS Genet; 2015 Jul; 11(7):e1005349. PubMed ID: 26147622
[TBL] [Abstract][Full Text] [Related]
34. APOL1 toxin, innate immunity, and kidney injury.
Limou S; Dummer PD; Nelson GW; Kopp JB; Winkler CA
Kidney Int; 2015 Jul; 88(1):28-34. PubMed ID: 25853332
[TBL] [Abstract][Full Text] [Related]
35. Kidney disease and APOL1.
Yusuf AA; Govender MA; Brandenburg JT; Winkler CA
Hum Mol Genet; 2021 Apr; 30(R1):R129-R137. PubMed ID: 33744923
[No Abstract] [Full Text] [Related]
36. Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.
Aliyu MH; Wudil UJ; Ingles DJ; Shepherd BE; Gong W; Musa BM; Muhammad H; Sani MU; Abdu A; Nalado AM; Atanda A; Ahonkhai AA; Ikizler TA; Winkler CA; Kopp JB; Kimmel PL; Wester CW
Trials; 2019 Jun; 20(1):341. PubMed ID: 31182139
[TBL] [Abstract][Full Text] [Related]
37. The evolving science of apolipoprotein-L1 and kidney disease.
Chen TK; Estrella MM; Parekh RS
Curr Opin Nephrol Hypertens; 2016 May; 25(3):217-25. PubMed ID: 27023839
[TBL] [Abstract][Full Text] [Related]
38. A focus on the association of Apol1 with kidney disease in children.
Ekulu PM; Nkoy AB; Adebayo OC; Kazadi OK; Aloni MN; Arcolino FO; Ngiyulu RM; Gini JE; Lepira FB; Van den Heuvel LP; Levtchenko EN
Pediatr Nephrol; 2021 Apr; 36(4):777-788. PubMed ID: 32253519
[TBL] [Abstract][Full Text] [Related]
39. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.
Ma L; Shelness GS; Snipes JA; Murea M; Antinozzi PA; Cheng D; Saleem MA; Satchell SC; Banas B; Mathieson PW; Kretzler M; Hemal AK; Rudel LL; Petrovic S; Weckerle A; Pollak MR; Ross MD; Parks JS; Freedman BI
J Am Soc Nephrol; 2015 Feb; 26(2):339-48. PubMed ID: 25012173
[TBL] [Abstract][Full Text] [Related]
40. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
